Ameet Nathwani, M.D., EVP of medical function at Sanofi, gives the inside scoop on what’s required when it comes to preparing a Big Pharma to be digital-health ready.
A summary from the BIO conference panel “Don’t Be Foreign To Foreign Affairs — How To Broker Biopharma Strategic Alliances And Partnerships Between International Stakeholders”
Alexis Howerton is a first-time pharma CEO who saw potential in an older drug class that had failed in its targeted indications. She then jumped feet first into obtaining the ideal candidate compound and starting a company to develop it.
“We had to decide whether to spend a lot of money to bring on a sales force and marketing team, and expand manufacturing to meet demand, or take our resources and refocus them on these rare disorders.”
Tom Wiggans, founder, chairman, and CEO of Dermira, provides an overview of the dermatology market, the impetus for founding Dermira, and transparently shares his experience regarding his company’s Phase 3 clinical trial failures.
Jeff Jonas, M.D., CEO of Sage Therapeutics, discusses how the company is preparing to launch a new CNS product likely to change the paradigm for how postpartum depression is treated.
From founding the company to funding it, the CEO of Aurinia Pharmaceuticals explains the genesis of the company and why he left retirement to return to guide the company.
When Viela Bio spun out of MedImmune last spring, it started with some assets well into development. Now it’s focusing on speed and continuity as it advances those assets through the clinic.
The biopharma industry has changed significantly during the past 10 years, and so has Life Science Leader. What will the next decade have in store for issues such as drug pricing and new therapeutic advances?
I imagine George Yancopoulos, profiled on this month’s cover, to have gained some of his life’s wisdom in a similar fashion to most people — by trying new things.
Tawni Koutchesfahani, director of manufacturing strategy at Relypsa, says pharmaceutical manufacturing must diversify if it is to thrive. That means the recruitment and retention of more women and more millennials.
Drawing from his 27 years in the pharma industry, Chris Garabedian shares useful lessons for combining business savvy and scientific leadership in drug development.
An exclusive interview with George Yancopoulos who talks about why his partnership with Len Schleifer has lasted so long and how “wild ideas” have served as the underlying theme to Regeneron.
Beginning her career with the query — how does biology cause disease? — Vicki Sato progressed to business, turning scientific understanding into new therapeutic drugs. Sato has been a biopharma leader since the industry’s formative years, helping drive the growth of Biogen and Vertex, and she is still guiding new companies today.
Tony Coles, M.D., chairman and CEO of Yumanity Therapeutics, discusses the decision to acquire Proteolix for $800 million when serving as the CEO of Onyx Pharmaceuticals.
Tony Coles, M.D., chairman and CEO of Yumanity Therapeutics, talks about the loss of Susan Lindquist, one of the company’s cofounders.
Ameet Nathwani, M.D., EVP of Sanofi’s medical function, discusses digital health joint venture with Verily Life Sciences, and good places to look for digital health top talent.
Amir Kalali, M.D., former global head of Quintiles (now IQVIA) neuroscience center of excellence, provides insight on why he decided to found an educational conference, The CNS Summit, while still working as a biopharmaceutical industry executive.
What current biopharma leaders have the potential to “transcend” beyond this industry? Chief Editor Rob Wright gives his top three choices.